Table 1. Response and survival data in each cohort.

Variable	NIVO 3	NIVO 1 + IPI 3	NIVO 3 + IPI 1
All patients, n	59	49	52
ORR, 95% CI (%)	12 [5–23]	24 [13–39]	8 [2–19]
Median PFS, 95% CI (mo)	1.5 (1.3–2.6)	2.2 (1.2–4.4)	1.5 (1.4–2.4)
12-month PFS rate, %	10	16	8
Median OS, 95% CI (mo)	6.2 (3.4–12.4)	6.9 (3.7–11.5)	4.8 (3.0–8.4)
12-month OS rate, 95% CI (%)	39 [26–52]	35 [22–49]	24 [13–37]
18-month OS rate, 95% CI (%)	25 [14–37]	28 [15–41]	13 [5–24]
Patients with PD-L1 ≥1%
ORR, 95% CI (%)	19 [4–46]	40 [12–74]	23 [5–54]
Median OS, 95% CI (mo)	NR	NR	NR
12-month OS rate, 95% CI (%)	34 [12–57]	50 [18–75]	23 [6–47]
18-month OS rate, 95% CI (%)	13 [2–35]	50 [18–75]	15 [3–39]
Patients with PD-L1 ≤1%
ORR, 95% CI (%)	12 [2–30]	22 [9–40]	0 [0–12]
Median OS, 95% CI (mo)	NR	NR	NR
12-month OS rate, 95% CI (%)	45 [25–63]	32 [16–48]	25 [11–42]
18-month OS rate, 95% CI (%)	28 [13–47]	24 [10–40]	8 [2–23]

NIVO 3, nivolumab 3 mg/kg; NIVO 1, nivolumab 1 mg/kg; IPI3, ipilimumab 3 mg/kg; IPI 1, ipilimumab 1 mg/kg; ORR, objective response rate; OS, overall survival; CI, confidence interval; NR, not reported.